Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity

Author

Moeini, Agrin

Sia, Daniela

Zhang, Zhongyang

Campreciós Figueras, Genís

Stueck, Ashley

Dong, Hui

Montal, Robert

Torrens, Laura

Martínez Quetglas, Iris

Fiel, Maria Isabel

Hao, Ke

Villanueva, Augusto

Thung, Swan N.

Schwartz, Myron

Llovet i Bayer, Josep Maria

Publication date

2018-03-01T17:55:20Z

2017-01-23

2018-03-01T17:55:20Z

Abstract

Background & Aims: Mixed hepatocellular cholangiocarcinoma (HCC-CCA) is a rare and poorly understood type of primary liver cancer. We aimed to perform a comprehensive molecular characterization of this malignancy.Methods: Gene expression profiling, DNA copy number detection, and exome sequencing using formalin-fixed samples from 18 patients with mixed HCC-CCA were performed, encompassing the whole histological spectrum of the disease. Comparative genomic analysis was carried out, using independent datasets of HCC (n = 164) and intrahepatic cholangiocarcinoma (iCCA) (n = 149).Results: Integrative genomic analysis of HCC-CCAs revealed that cholangiolocellular carcinoma (CLC) represents a distinct biliaryderived entity compared with the stem-cell and classical types. CLC tumors were neural cell adhesion molecule (NCAM) positive (6/6 vs. 1/12, p < 0.001), chromosomally stable (mean chromosomal aberrations 5.7 vs. 14.1, p = 0.008), showed significant upregulation of transforming growth factor (TGF)-beta signaling and enrichment of inflammation-related and immune response signatures (p < 0.001). Stem-cell tumors were characterized by spaltlike transcription factor 4 (SALL4) positivity (6/8 vs. 0/10, p < 0.001), enrichment of progenitor-like signatures, activation of specific oncogenic pathways (i.e., MYC and insulin-like growth factor [IGF]), and signatures related to poor clinical outcome. In the classical type, there was a significant correlation in the copy number variation of the iCCA and HCC components, suggesting a clonal origin. Exome sequencing revealed an average of 63 non-synonymous mutations per tumor (2 mean driver mutations per tumor). Among those, TP53 was the most frequently mutated gene (6/21, 29%) in HCC-CCAs.Conclusions: Mixed HCC-CCA represents a heterogeneous group of tumors, with the stem-cell type characterized by features of poor prognosis, and the classical type with common lineage for HCC and iCCA components. CLC stands alone as a distinct biliary-derived entity associated with chromosomal stability and active TGF-b signaling.Lay summary: Molecular analysis of mixed hepatocellular cholangiocarcinoma (HCC-CCA) showed that cholangiolocellular carcinoma (CLC) is distinct and biliary in origin. It has none of the traits of hepatocellular carcinoma (HCC). However, within mixed HCC-CCA, stem-cell type tumors shared an aggressive nature and poor outcome, whereas the classic type showed a common cell lineage for both the HCC and the intrahepatic CCA component. The pathological classification of mixed HCC-CCA should be redefined because of the new molecular data provided. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Document Type

Article
Accepted version

Language

English

Subjects and keywords

Càncer de fetge; Genètica molecular humana; Factors de creixement; Liver cancer; Human molecular genetics; Growth factors

Publisher

Elsevier

Related items

Versió postprint del document publicat a: https://doi.org/10.1016/j.jhep.2017.01.010

Journal of Hepatology, 2017, vol. 66, num. 5, p. 952-961

https://doi.org/10.1016/j.jhep.2017.01.010

info:eu-repo/grantAgreement/EC/H2020/667273/EU//HEP-CAR

info:eu-repo/grantAgreement/EC/FP7/259744/EU//HEPTROMIC

Rights

cc-by-nc-nd (c) Elsevier, 2017

http://creativecommons.org/licenses/by-nc-nd/3.0/es